Enobia Pharma enobia.com


Enobia Pharma develops therapies to treat serious genetic bone disorders for which there are no approved treatments. The company's lead product, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for hypophosphatasia and is currently in Phase 2 clinical studies. In December 2011, Enboia Pharma was acquired by Alexion Pharmaceuticals. The valuation of Enbia Pharma was $610 million.

Enobia Pharma develops therapies to treat serious genetic bone disorders for which there are no approved treatments. The company's lead product, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted en...Show all

Company (Acquired)

Phone:

Fax:

2901, Rachel Street East
#23
Montreal, H1W 4A4
Quebec, Canada

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Enobia Pharma $131.5M Dec 29, 2011

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Enobia Pharma Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 9 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Bone delivery conjugates and method of using same to target proteins to bone Jun 03, 2010 Jun 14, 2011 Patent
Bone delivery conjugates and method of using same to target proteins to bone Apr 21, 2005 Jul 27, 2010 Patent